

## REMARKS

### **I. Status of the Claims/Amendments to Specification/Sequence Listing/Telephonic I Interview with Examiner Tongue/Supplemental Amendment/Substitute Specification/Sequence Listing Submission**

Claims 1 – 12, 18-22, 24-31, 35 and 37-49 were previously withdrawn.

Claims 15-17, 23, 32-34 and 36 were previously cancelled.

Claims 13 and 14 have been amended.

Claims 50-55 have been added.

Claims 13-14 and 50-55 are pending.

New claims 50-55 claim specific SEQ ID NO identifiers in claim 13 (Claims 51-54) and claim 14 (claim 55). No new matter has been added.

The following materials are included with this amendment:

1. Sequence Listing: paper copy and Electronic Disc copy;
2. Statement under 37 CFR §§1.821-1.825;
3. Substitute Specification; and
4. Figure 11 (marked-up).

A Substitute Specification is included here. The specific pages/lines in the application that include SEQ ID NO identifiers are as follows:

Page 18, line 21 to page 20, line 31 (Tables 1, 2 and 3);  
Page 28, lines 5-24;  
Page 59, lines 9-10;  
Page 60, line 10 and lines 16-19;  
Page 61, lines 18-19;  
Page 62, lines 11-16;  
Page 62, line 21 to page 64, line 12  
Page 70, line 6 to page 71, line 1;  
Page 78, line 21 to page 79, line 13;  
Page 80, line 5 to 12;  
Page 80, line 25 to page 82, line 3;  
Page 84, line 21 to page 86, line 10;  
Page 87, lines 18-27.

## **II. Interview with Examiner Tongue**

Examiner Tongue contacted Applicant's representative, Denise Mayfield, on May 15, 2008. The Examiner indicated there were resolvable formalities. The claims pending would then be considered to be in a condition for allowance.

The Examiner indicated that the Figures and Specification needed to be amended so as to be consistent with a proper Sequence Listing submission. Attached herewith is a Sequence Listing Submission in compliance with United States guidelines for same, as well as a substitute specification that incorporates the proper sequence listing identifiers where appropriate. No new matter has been added.

An additional issue raised by the Examiner concerned clarification as the claimed subject matter as relating to fibrinogen binding protein or to adhesion factor. The claims have been amended to further define a fibrinogen binding protein.

## **III. Conclusion**

The present paper is submitted to place the application and claims in condition for allowance. Applicants respectfully request that the present application and claims be allowed to issue.

Should the Examiner have any questions, applicant's undersigned representative earnestly requests a telephone conference.

The Commissioner is hereby authorized to charge deposit account 02-1818 for any fees which are due and owing.

Respectfully submitted,

BELL, BOYD & LLOYD LLP

BY Denise L. Mayfield  
Denise L. Mayfield  
Reg. No. 33,732  
Customer No. 29180

Dated: August 5, 2008